Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects-A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

被引：2
|
作者：
He, Kun
Wei, Fang
Chen, Hong
Zhang, Yanyan
Sheng, Zhen
Wen, Qing
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-763-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
763-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects
    Garey, Kevin W.
    Begum, Khurshida
    Lancaster, Chris
    Gonzales-Luna, Anne
    Dinh Bui
    Mercier, Julie
    Yue, Corinne Seng
    Ducharme, Murray P.
    Hu, Ming
    Vince, Bradley
    Silverman, Michael H.
    Alam, M. Jahangir
    Kankam, Martin
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3635 - 3643
  • [32] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
    Pratt, Edward J.
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah A.
    Sloop, Kyle
    Benson, Charles
    DIABETES, 2022, 71
  • [33] A phase 2, randomized, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics & pharmacogenetics of CC-220 in subjects with SLE
    Werth, V.
    Furie, R.
    Hough, D.
    Korish, S.
    Weiswasser, M.
    Azarian, A.
    Schafer, P.
    Delev, N.
    Choi, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S65 - S65
  • [34] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants
    Li, Yunfei
    Zhang, Hua
    Pandya, Hitesh
    Miao, Liyan
    Reid, Fred
    Jimenez, Eulalia
    Sadiq, Muhammad Waqas
    Moate, Rachel
    Lei, Alejhandra
    Zhou, Xiao-Hong
    Kell, Chris
    Ding, Junjie
    Zhang, Guanlin
    Zhao, Lina
    Ge, Xiaoyun
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (06): : 665 - 671
  • [35] A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects
    Ermer, James
    Martin, Patrick
    Corcoran, Mary
    Matsuo, Yumiko
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2020, 40 (01) : 16 - 29
  • [36] A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease
    Galasko, Douglas
    Farlow, Martin R.
    Lucey, Brendan P.
    Honig, Lawrence S.
    Elbert, Donald
    Bateman, Randall
    Momper, Jeremiah
    Thomas, Ronald G.
    Rissman, Robert A.
    Pa, Judy
    Aslanyan, Vahan
    Balasubramanian, Archana
    West, Tim
    Maccecchini, Maria
    Feldman, Howard H.
    ALZHEIMERS RESEARCH & THERAPY, 2024, 16 (01)
  • [37] A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CB03-154 in Healthy Subjects
    Zhu, Minjuan
    Hua, Bo
    Li, Baini
    Guo, Ruoling
    Liu, Gang
    Liu, Xiuxiu
    Wan, Hui
    Yao, Shuran
    Song, Chao
    Dou, Jinhui
    Zhang, Xin
    Lu, Zhihong
    Zhou, Xiaolin
    Chen, Huanming
    Gonen, Ofer
    ANNALS OF NEUROLOGY, 2024, 96 : S179 - S180
  • [38] A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
    Choi, Jae Duk
    Baek, Seungjae
    Kim, Youngmin
    Eun, Kahee
    Kwon, Se Chang
    Morrow, Linda
    Hompesch, Marcus
    Kang, Jahoon
    DIABETES, 2019, 68
  • [39] A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
    Matsuno, Kumi
    Tanaka, Shingo
    Hashimoto, Takamasa
    Nakamichi, Hiroyuki
    Kagawa, Tomoya
    Koumura, Emiko
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (11): : 1516 - 1524
  • [40] A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF OCR-002 IN HEALTHY VOLUNTEERS
    Jochelson, P.
    van de Wetering, J. L.
    Bornstein, J.
    Resler, M.
    Anderson, K.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S70 - S70
12345